L01DB01 • doxorubicin • Antineoplastic and immunomodulating agents | Cytotoxic antibiotics and related substances | Anthracyclines and related substances
Doxorubicinum is a chemotherapy drug used for the treatment of various types of cancer, including breast cancer, leukemia, and lymphoma. It belongs to the anthracycline class and works by inhibiting DNA synthesis in cancer cells, preventing their division and growth.
The medication is administered intravenously, usually as part of a specific regimen, under the supervision of an oncologist. It is effective in reducing tumor size and slowing disease progression.
Side effects may include nausea, vomiting, hair loss, bone marrow suppression, and, in rare cases, cardiac toxicity. Close monitoring is essential during treatment.
Consult your doctor to discuss the benefits and risks of treatment with Doxorubicinum. This medication must be administered exclusively in controlled environments, such as hospitals.
Substance: doxorubicin
Date of last drug list: 10-04-2026
Commercial code: W65789004
Concentration: 2mg / ml
Pharmaceutical form: concentrate for solution for infusion
Quantity: 1
Product type: generic
Price: 42.76 RON
Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).
Manufacturer: ACCORD HEALTHCARE LIMITED - MAREA BRITANIE
Holder: ACCORD HEALTHCARE POLSKA SP. Z O.O. - POLONIA
Number: 10647/2018/02
Shelf life: 18 months-after packing for marketing;after the first opening of the bottle-it is used immediately